Nov 2018
A new survey has found that even though the cost of medicinal cannabis has significantly decreased over the past year the pricing is still too high for many Australians. Patients are required to cover all of the cost of their treatment as no cannabis medications are subsidised by the Pharmaceutical Benefits Scheme (PBS). As a result many of them are looking for cheaper alternatives on the black market. Read the article here.
We’re thrilled to announce we have received our export licence from the Drug Control Section of the ODC (Office of Drug Control). We’re firmly on course to continue to lead the way and be the first medicinal cannabis company in Australia to export cannabis flower to the EU since export was legalised in 2018.
We have successfully passed three consecutive TGO93 and TGO100 tests on our medicinal cannabis products since our first commercial harvest at the end of 2019.
One of ANTG’s proprietary medicinal cannabis strains, EVE Cannabis Indica, has been listed on the Australian Register of Therapeutic Goods (ARTG). The ARTG is a reference of therapeutic goods that can lawfully be supplied in or exported from Australia.
We are focused on research and development, partnering with leading scientists and medical institutions to develop cannabinoid medicines that offer safe and effective therapeutic benefits.
LEARN ABOUT ANTG HERE >